200 first imitations will be approved! Major companies’ hot imitation products were exposed.

1.Expansion business: Yuyue medical re acquisition, 100% holding

Recently, the enterprise check app shows that Jiangsu Lerun contact lens Co., Ltd. has undergone industrial and commercial changes, the original shareholders Jiangsu Hongyi Garden Construction Engineering Co., Ltd. and Danyang xintongqiu optical glasses Co., Ltd. withdrew, and the new shareholder Yuyue medical (002223) holds 100%. It is worth mentioning that as early as 2019, Yuyue spent nearly 80 million yuan to acquire two ophthalmic machinery enterprises.

2.On May 24, the official website of Zhejiang Pharmaceutical Machinery Procurement Center released a notice on the ranking of drug warehousing amount in 2021, and the relevant information of the top 200 products was officially announced. Top10 was dominated by multinational pharmaceutical companies, and clopidogrel bisulfate tablets from China Stone Pharmaceutical Group and Europe Italy Pharmaceutical Co., Ltd., a domestic pharmaceutical company, occupied Top11.

3.Under a series of policies, domestic innovative drugs have ushered in an intensive harvest period, and pharmaceutical enterprises have also stepped into the achievement exchange period. According to the data of micnet, since 2011, nearly 90 domestic class 1 new drugs (including class 1 and 1.1, excluding vaccines, the same below) have been approved for listing, and 15 pharmaceutical companies have approved 2 or more varieties. The advantages of traditional big pharma are prominent, and Hengrui is firmly in the first place. After hausen, head biotech is not willing to be outdone, and Baiji Shenzhou, Hehuang pharmaceutical and zaiding pharmaceutical are tied for the third place.

4.Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., a subsidiary of Guangzhou Pharmaceutical Group, one of the world’s top 500 enterprises, announced on the evening of May 30 that its Baiyunshan Pharmaceutical General Factory received a letter from the U.S. FDA (i.e. the U.S. Food and Drug Administration) on May 29 approving bys10 tablets to be used in clinical trials for the treatment of advanced solid tumors with RET fusion or mutation. Baiyunshan Pharmaceutical General Factory plans to carry out an open, multi center phase I clinical trial of the new drug for the above indications when the conditions are met in the near future.

5.The contrast agent market is booming again. Kelun pharmaceutical has won the first imitation and Hengrui medicine to go to sea. According to the data of Intranet, in 2021, the terminal contrast agent sales of public medical institutions in China exceeded 17billion yuan, a year-on-year increase of 13.05%; Hengrui pharmaceutical, General Electric pharmaceutical and Yangtze River Pharmaceutical ranked among the top three; The sales volume of five products exceeded 1billion yuan, led by iodixanol injection. At present, 10 kinds of contrast agents (40 specifications) have been evaluated, and the iodophor has met the conditions for centralized collection; 12 types of contrast agents (23 product specifications) are on the market for review, and Beite pharmaceutical is the first to imitate them.

6.On June 7, Huiyu pharmaceutical announced that its wholly-owned subsidiary Seacross pharmaceuticals’ prosafel injection obtained the registration approval in the UK, making it the first enterprise to obtain the approval of the generic drug in the UK. Since this year, Huiyu pharmaceutical injection products have been approved at home and abroad.

7.200 first imitations will be approved! Major companies’ hot imitation products were exposed.

In recent years, the first generic drugs have been encouraged at the national level. While actively distributing innovative drugs, the leading pharmaceutical companies with high R & D level have also accelerated the “imitation” work. Since 2018, there have been about 200 products that have been applied for imitation listing and are under review, and no domestic approval has been obtained for the same products. It is expected that they will be approved for listing after 2022, with the top five hundred billion market heat.

8.Humanwell shows its strength! 20 class 1 new drugs and 18 improved new drugs are hot.

In recent years, humanwell pharmaceutical, the leader of anesthesia and sedation, has continuously improved and consolidated its core competitiveness through “focus, innovation and internationalization”. Recently, the company announced that it would spend more than 1.6 billion yuan to purchase property assets to integrate internal resources and expand its capabilities. Among them, the property assets purchased by the innovative drug research and development center will be used as the biomedical “mass entrepreneurship and innovation” base to increase the innovation layout. In the first half of 2022, the company has two more class 1 new drugs approved for clinical use, and the first improved new drug is rushing to the market. The first imitation of the heavy children’s drug chlorbazam tablets has also attracted much attention. In addition, three major products are about to meet the seventh batch of National acquisitions.

9.Zhengda sunny! 58 class 1 new drugs and 9 first imitation sprints.

Recently, the product line of Zhengda Tianqing pharmaceutical has made new progress: the production of tq-b3101 capsule, a new class 1 anti-tumor drug, was reported, the third domestic sophopovir tablet was approved, and tqc2938 injection, a new class 1 anti asthma drug, was approved for clinical use At present, Zhengda Tianqing Pharmaceutical Co., Ltd. has 73 new drugs (58 class 1 new drugs) in the stage of clinical application or above, of which 14 new drugs (5 class 1 new drugs) are in the stage of phase III or above, and the listing is expected; In terms of generic drugs, 54 varieties have been evaluated (21 are the first), 8 drugs have been included in the seventh batch of centralized purchase, and 15 newly registered and declared varieties are under review, of which 9 have not been approved for the first time (including the first copy of the dosage form).

JinDun Medical has long-term scientific research cooperation and technology grafting with Chinese universities. With Jiangsu’s rich medical resources, it has long-term trade relations with India, Southeast Asia, South Korea, Japan and other markets. It also provides market and sales services in the whole process from intermediate to finished product API. Utilize the accumulated resources of Yangshi Chemical in fluorine chemistry to provide special chemical customization services for partners. Provide process innovation and impurity research services to target customers.